359 related articles for article (PubMed ID: 34206945)
1. Shared Biological Pathways between Antipsychotics and Omega-3 Fatty Acids: A Key Feature for Schizophrenia Preventive Treatment?
Frajerman A; Scoriels L; Kebir O; Chaumette B
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206945
[TBL] [Abstract][Full Text] [Related]
2. [Membrane lipids in schizophrenia and early phases of psychosis: Potential biomarkers and therapeutic targets?].
Frajerman A; Kebir O; Chaumette B; Tessier C; Lamazière A; Nuss P; Krebs MO
Encephale; 2020 Jun; 46(3):209-216. PubMed ID: 32151446
[TBL] [Abstract][Full Text] [Related]
3. A meta-analysis of placebo-controlled trials of omega-3 fatty acid augmentation in schizophrenia: Possible stage-specific effects.
Chen AT; Chibnall JT; Nasrallah HA
Ann Clin Psychiatry; 2015 Nov; 27(4):289-96. PubMed ID: 26554370
[TBL] [Abstract][Full Text] [Related]
4. Lipidomics reveals early metabolic changes in subjects with schizophrenia: effects of atypical antipsychotics.
McEvoy J; Baillie RA; Zhu H; Buckley P; Keshavan MS; Nasrallah HA; Dougherty GG; Yao JK; Kaddurah-Daouk R
PLoS One; 2013; 8(7):e68717. PubMed ID: 23894336
[TBL] [Abstract][Full Text] [Related]
5. Ndel1 oligopeptidase activity as a potential biomarker of early stages of schizophrenia.
Dal Mas C; Nani JV; Noto C; Yonamine CM; da Cunha GR; Mansur RB; Ota VK; Belangero SI; Cordeiro Q; Kapczinski F; Brietzke E; Bressan RA; Gadelha A; Hayashi MAF
Schizophr Res; 2019 Jun; 208():202-208. PubMed ID: 30857875
[TBL] [Abstract][Full Text] [Related]
6. Differences in omega-3 and omega-6 polyunsaturated fatty acid consumption in people at ultra-high risk of psychosis, first-episode schizophrenia, and in healthy controls.
Pawełczyk T; Trafalska E; Pawełczyk A; Kotlicka-Antczak M
Early Interv Psychiatry; 2017 Dec; 11(6):498-508. PubMed ID: 26279283
[TBL] [Abstract][Full Text] [Related]
7. A randomised, double-blind, placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at-risk mental states (NAYAB): study protocol.
Qurashi I; Chaudhry IB; Khoso AB; Farooque S; Lane S; Husain MO; Chu S; Sarginson J; Hamarani M; Naqvi HA; Razzaque B; Minhas FA; Yung AR; Deakin JFW; Husain N
Trials; 2017 Nov; 18(1):524. PubMed ID: 29121974
[TBL] [Abstract][Full Text] [Related]
8. [Stress and psychotic transition: A literature review].
Chaumette B; Kebir O; Mam Lam Fook C; Bourgin J; Godsil BP; Gaillard R; Jay TM; Krebs MO
Encephale; 2016 Aug; 42(4):367-73. PubMed ID: 27161263
[TBL] [Abstract][Full Text] [Related]
9. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study.
Sivrioglu EY; Kirli S; Sipahioglu D; Gursoy B; Sarandöl E
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1493-9. PubMed ID: 17688987
[TBL] [Abstract][Full Text] [Related]
10. Polyunsaturated fatty acid supplementation for schizophrenia.
Joy CB; Mumby-Croft R; Joy LA
Cochrane Database Syst Rev; 2003; (2):CD001257. PubMed ID: 12804400
[TBL] [Abstract][Full Text] [Related]
11. NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders.
Markulev C; McGorry PD; Nelson B; Yuen HP; Schaefer M; Yung AR; Thompson A; Berger G; Mossaheb N; Schlögelhofer M; Smesny S; de Haan L; Riecher-Rössler A; Nordentoft M; Chen EYH; Verma S; Hickie I; Amminger GP
Early Interv Psychiatry; 2017 Oct; 11(5):418-428. PubMed ID: 26279065
[TBL] [Abstract][Full Text] [Related]
12. Omega-3 fatty acids reduce cardiometabolic risk in first-episode schizophrenia patients treated with antipsychotics: Findings from the OFFER randomized controlled study.
Pawełczyk T; Grancow-Grabka M; Żurner N; Pawełczyk A
Schizophr Res; 2021 Apr; 230():61-68. PubMed ID: 33684737
[TBL] [Abstract][Full Text] [Related]
13. Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects.
Müller N; Myint AM; Schwarz MJ
Curr Pharm Des; 2011; 17(2):130-6. PubMed ID: 21361867
[TBL] [Abstract][Full Text] [Related]
14. New developments in the pharmacotherapy of schizophrenia.
Fleischhacker WW
J Neural Transm Suppl; 2003; (64):105-17. PubMed ID: 12830932
[TBL] [Abstract][Full Text] [Related]
15. Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia.
Mahadik SP; Pillai A; Joshi S; Foster A
Int Rev Psychiatry; 2006 Apr; 18(2):119-31. PubMed ID: 16777666
[TBL] [Abstract][Full Text] [Related]
16. Salivary cortisol in early psychosis: New findings and meta-analysis.
Chaumette B; Kebir O; Mam-Lam-Fook C; Morvan Y; Bourgin J; Godsil BP; Plaze M; Gaillard R; Jay TM; Krebs MO
Psychoneuroendocrinology; 2016 Jan; 63():262-70. PubMed ID: 26520686
[TBL] [Abstract][Full Text] [Related]
17. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics.
Khan MM; Evans DR; Gunna V; Scheffer RE; Parikh VV; Mahadik SP
Schizophr Res; 2002 Nov; 58(1):1-10. PubMed ID: 12363384
[TBL] [Abstract][Full Text] [Related]
18. Auditory Event-Related Potentials in Antipsychotic-Free Subjects With Ultra-High-Risk State and First-Episode Psychosis.
Hsieh MH; Lin YT; Chien YL; Hwang TJ; Hwu HG; Liu CM; Liu CC
Front Psychiatry; 2019; 10():223. PubMed ID: 31037058
[No Abstract] [Full Text] [Related]
19. Neuropathology markers and pathways associated with molecular targets for antipsychotic drugs in postmortem brain tissues: exploration of drug targets through the Stanley Neuropathology Integrative Database.
Kim S; Zavitsanou K; Gurguis G; Webster MJ
Eur Neuropsychopharmacol; 2012 Oct; 22(10):683-94. PubMed ID: 22356822
[TBL] [Abstract][Full Text] [Related]
20. Niacin Skin Sensitivity Is Increased in Adolescents at Ultra-High Risk for Psychosis.
Berger GE; Smesny S; Schäfer MR; Milleit B; Langbein K; Hipler UC; Milleit C; Klier CM; Schlögelhofer M; Holub M; Holzer I; Berk M; McGorry PD; Sauer H; Amminger GP
PLoS One; 2016; 11(2):e0148429. PubMed ID: 26894921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
